--- title: 'Director Clinical Pharmacology & DMPK at Alumis' canonical: 'https://feeny.ai/job/director-clinical-pharmacology-dmpk-alumis-south-san-francisco-pcqbb14d2vdt' type: 'job' last_seen: '2026-09-08' --- # Director Clinical Pharmacology & DMPK at Alumis - **Company:** Alumis - **Location:** South San Francisco, CA - **Posted:** 2026-03-12 - **Last confirmed live:** 2026-09-08 - **Apply:** https://job-boards.greenhouse.io/alumis/jobs/5150963008 ## Job description Alumis Inc. is a precision medicines company with the mission to transform the lives of patients with autoimmune diseases. Even with treatment innovations of the last two decades, many patients with immunologic conditions continue to suffer - our goal is to fundamentally change the outcomes for these patients. Alumis is seeking a Director of Clinical Pharmacology & DMPK to drive clinical pharmacology strategy and PK/PD modeling for our small-molecule programs in immune-mediated diseases. This role partners closely with cross-functional teams and reports to the Head of Clinical Pharmacology & DMPK. Specific responsibilities include but are not limited to: - Lead clinical pharmacology strategy, dose selection, and PK/PD and biomarker planning across early and late-stage programs. - Conduct and interpret PK, PK/PD, exposure–response, and simulation analyses using tools such as NONMEM, WinNonlin, R, Python, and Simcyp. - Integrate translational and nonclinical PK/PD data to support FIH dose projections and DDI assessments. - Oversee bioanalytical CROs, ensuring high-quality PK/PD/biomarker data and GLP/GCP compliance. - Partner with Clinical Operations on sample management and protocol design. - Communicate quantitative findings clearly and contribute to regulatory documents (protocols, IBs, INDs, NDAs, IMPDs). - Collaborate across Clinical Development, Biostats/Data Science, Nonclinical, and Program Management. Key Requirements and Qualifications: - PhD, PharmD, or equivalent in Pharmacokinetics, Pharmacology, or related field. - 6 to 8+ years of industry experience in Clinical Pharmacology, DMPK, or Quantitative Pharmacology. - Strong expertise in PK, PK/PD, DMPK, and translational sciences. - Proficiency with modeling/simulation platforms (NONMEM, WinNonlin, Simcyp, R, Python). - Excellent communication, organization, and ability to work independently in a fast-paced environment. The salary range for this position is $200,000 USD to $240,000 USD annually. This salary range is an estimate, and the actual salary may vary based on the Company’s compensation practices. This position is located in South San Francisco, CA and employees are expected to be onsite Tuesday-Thursday. Alumis compensation packages include generous stock option grants for all employees as well as an annual bonus program. Other benefits include: - Health insurance premiums paid at 90% for employee, 80% for dependents - Free access to Genentech Bus & Ferry Share program - $100 monthly cell phone stipend - Unlimited PTO for Exempt employees - Free onsite gym and a kitchen stocked with yummy snacks and drinks! We are a hard-working, collaborative team on a mission to transform patient’s lives-- and we aspire to elevate, challenge and nurture one another along the way. Alumis Inc. is an equal opportunity employer. ## About Alumis ## Company Overview - **One-liner**: Alumis is a public biotechnology company pioneering precision-targeted therapies for immune-mediated diseases, with a late-stage pipeline and proprietary data analytics platform. - **Entity Type**: Public (ticker symbol not confirmed in available sources; reports quarterly financials as a public company) - **Headquarters**: South San Francisco, California, United States - **Founded**: 2021 - **Founders**: Incubated by Foresite Labs; leadership includes Martin Babler (President, CEO and Chairman of the Board) ## Core Business - **Primary industry**: Biotechnology – immune-mediated disease therapeutics. - **Target customers**: Patients with immune-mediated diseases (e.g., psoriasis, lupus), physicians, and healthcare systems (B2B/B2C). - **Mission statement**: Transform treatment for immune-mediated diseases, empower people to reimagine their lives. ## Products & Services - **Envudeucitinib (oral TYK2 inhibitor)**: Late-stage candidate for plaque psoriasis; Phase 3 trials demonstrated early and robust improvements in skin clearance, quality of life, and psoriasis symptoms. Designed as a next-generation oral therapy. - **Proprietary Data Analytics Platform**: Internal platform that integrates scientific insights to select the right target, molecule, indication, patient, and endpoint. - **Pipeline of targeted therapies**: Additional programs for other immune-mediated diseases (specific indications not publicly detailed), all aiming to replace broad immunosuppression with precise treatments. ## Market Standing - **Valuation/Market Cap**: Not disclosed in available sources. - **Key Metric**: Total funding (private) not publicly available; as a public company, annual revenue is not yet disclosed (likely pre-revenue or early commercial stage). - **Notable Investors/Partners**: Incubated by Foresite Labs; board includes members from Foresite Capital, Arvinas, and other biotech leadership. - **Growth Signals**: - Active late-stage Phase 3 trials with positive results for plaque psoriasis (March 2026). - Employee headcount of 246 (as of mid-2026), growing ~1.3% monthly. - 13 active job postings, up 30% in the month prior. - Listed job openings span Clinical Development, Commercial, Research & Technical Operations, and G&A. ## Competitive Advantages - **Precision approach**: Proprietary data analytics platform enables smarter target selection and clinical trial design, reducing failure risk. - **Late-stage portfolio**: Envudeucitinib already in Phase 3, targeting a large market (plaque psoriasis) with potential to become a leading oral therapy. - **Experienced leadership**: Deep biotech expertise from CEO Martin Babler and a seasoned leadership team. - **Focus on patient outcomes**: Differentiates from broad immunosuppressants by aiming for efficacy without life-limiting side effects. ## Strategic Focus - Advance Envudeucitinib through regulatory approval and launch for plaque psoriasis. - Expand pipeline into additional immune-mediated indications (rheumatology, lupus, etc.). - Leverage data analytics to optimize clinical development and commercialization. - Build commercial infrastructure (hiring VP of Medical Affairs, Director of Market Access, etc.). ## Why Work Here - **Culture**: Emphasizes openness, collaboration, and respect; employee-led Culture Team drives engagement, growth, and inclusion. - **Values**: Challenge conventional wisdom, nurture teammates, elevate each other. - **Benefits**: Medical, dental, vision, 401k, unlimited time off, pet insurance, Employee Stock Purchase Plan, commuter benefits (including company-paid access to Genentech Bus and Ferry lines). - **Work Environment**: Mostly based in South San Francisco; some roles offer remote flexibility (indicated as "United States" in job listings). Hybrid likely for local roles. - **Growth**: High-performance, mission-driven environment with expanding headcount and pipeline; opportunity to impact transformative therapies. - **Job Openings**: Currently hiring for senior scientific, clinical, commercial, and operational roles (Associate Director Biostatistics, Vice President Medical Affairs, Director Market Access, etc.). ## Sources 1. [alumis.com – Company Website](https://www.alumis.com/) 2. [alumis.com – Careers Page](https://www.alumis.com/careers/) 3. [alumis.com – About / Leadership](https://www.alumis.com/about/) 4. [alumis.com – Job Opportunities](https://www.alumis.com/careers/job-opportunities/) 5. [LinkedIn – Alumis Company Profile](https://www.linkedin.com/company/alumis-com) ## Other roles at Alumis - [Director, Medical Affairs](https://feeny.ai/job/director-medical-affairs-alumis-south-san-francisco-t1kf4ejqcaxe) — South San Francisco, CA - [Senior Manager, People & Culture Operations](https://feeny.ai/job/senior-manager-people-culture-operations-alumis-south-san-francisco-5h92h9gc4d8j) — South San Francisco, CA - [Medical Science Liaison](https://feeny.ai/job/medical-science-liaison-alumis-united-states-nf1r6b2qqmk1) — United States - [Medical Outcomes Liaison](https://feeny.ai/job/medical-outcomes-liaison-alumis-united-states-6y700jmft07k) — United States - [Senior Director, Medical Strategy and Operations](https://feeny.ai/job/senior-director-medical-strategy-and-operations-alumis-united-states-bsawqvwmzrka) — United States - [Senior Scientist I Analytical Development](https://feeny.ai/job/senior-scientist-i-analytical-development-alumis-south-san-francisco-myefvg693tkw) — South San Francisco, CA - [Senior Scientist, Drug Product Development](https://feeny.ai/job/senior-scientist-drug-product-development-alumis-south-san-francisco-rgdk6p0j7s02) — South San Francisco, CA - [Senior/Executive Medical Director, Clinical Development (New Indications)](https://feeny.ai/job/senior-executive-medical-director-clinical-development-new-indications-alumis-an6hzxfmf4bz) — South San Francisco, CA - [Vice President Corporate Communications & Investor Relations](https://feeny.ai/job/vice-president-corporate-communications-investor-relations-alumis-south-san-epfvvrpa9016) — South San Francisco, CA - [Vice President, Medical Affairs](https://feeny.ai/job/vice-president-medical-affairs-alumis-south-san-francisco-wf29rz4etq59) — South San Francisco, CA